How did Medline reconcile 12% top-line growth and a raised organic sales outlook with a lower full-year adjusted EBITDA

The short reconciliation

Medline did not say the strong quarter automatically meant a stronger full year. In the same report, it raised one forecast and cut another because the two forecasts were affected by different things: organic sales reflected demand, while adjusted EBITDA guidance reflected costs, investments, and a special treatment of tariff refunds [1][6][18].

What the Q2 numbers show

• Q2 net sales rose 11.6% to $7.7 billion, which is the roughly “12% top line growth” management described [10][11][44].
• Q2 organic sales grew 11.5% [31].
• Medline raised its full-year organic sales growth outlook to 9.0%–10.0%, up from 8.5%–9.5%, because customer demand was strong [18][39].
• Q2 adjusted EBITDA actually grew 13.4% to about $1.06 billion, helped by higher net sales and net tariff refund benefits [14][29].
• At the same time, Medline lowered its full-year 2026 adjusted EBITDA outlook to $3.3 billion–$3.4 billion, from $3.5 billion–$3.6 billion [17][40].

So the short-term profit number looked fine, but the forward-looking profit number did not.

Why Medline cut the full-year profit guidance

The company’s official explanation listed four main headwinds:

• Higher-than-expected inflation from the Middle East conflict, including higher fuel and product costs that Medline was absorbing rather than passing on to customers [1][87].
• Increased operational investments to support customer demand; Medline said it was adding labor three to six months before revenue from that demand arrived [1][94].
• Quality remediation efforts, including delays getting recalled products back on the market [1][89].
• Softness in the retail channel, which Medline called an unplanned headwind and partly Medline-specific because it lost business at a large retail customer [1][96][97].

Management also framed the cut this way: around 25% of the reduction came from external factors and around 75% from internal factors such as operational investment, quality remediation, and retail softness [92]. It estimated that roughly half of the earnings impact was temporary and half was more permanent [91].

The tariff refund detail that ties it together

One important technical point is how Medline treated tariff refunds in the two outlooks.

After the Supreme Court ruled that the IEEPA tariffs were unauthorized, Medline recognized $243 million of net tariff refund benefits in the first half of 2026, consisting of $332 million of refunds that reduced cost of goods sold, partly offset by $89 million of customer repayments that reduced net sales [32][38].

Medline then said its full-year organic sales outlook reflected the tariff customer repayments, while its adjusted EBITDA outlook did not reflect the benefit of tariff refunds [6][41][64]. Management said the $243 million net tariff refund benefit was excluded from adjusted EBITDA guidance to show true underlying performance, and that underlying Q2 adjusted EBITDA was $817 million once that benefit was removed [85].

That helps explain the apparent contradiction. The sales outlook rose because demand was strong, but the profit outlook was set on a stricter basis that excluded one-time tariff benefits and included a long list of cost headwinds [1][6][85].